Clinical Trial Update: A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH [Phase 3]

View source ↗

Summary

Phase 3 study update evaluating MSDC-0602K for glycemic control and cardiovascular outcomes in pre-diabetes/Type 2 diabetes with NAFLD/NASH; status not specifie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis
• Type 2 Diabetes Mellitus

Drugs mentioned

• MSDC-0602K (MSDC-0602K)

Snippet

Sponsor: Cirius Therapeutics, Inc. | Conditions: Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis | Phase 3 | Status: UNKNOWN